Northbridge Industrial S... (LSE:NBI)
Historical Stock Chart
From Jul 2019 to Jul 2024
Semi-Annual Changes to the NASDAQ Biotechnology Index
NEW YORK, Nov. 13 /PRNewswire-FirstCall/ -- The Nasdaq Stock Market, Inc.
("NASDAQ") (BULLETIN BOARD: NDAQ) announced today the results of the semi-
annual re-ranking of the NASDAQ Biotechnology Index(R) , which will become
effective with the market open on Monday, November 24, 2003.
The re-ranking will result in 55 securities being added to the Index. As
announced on November 11, 2003, NASDAQ will reclassify its companies according
to the FTSE Global Classification System(TM). The first step in this process is
basing the NASDAQ Biotechnology Index on FTSE's biotechnology and pharmaceutical
sub-sectors. The securities that meet the classification criteria then must
meet other Index eligibility criteria including listing on the NASDAQ National
Market and meeting minimum requirements for market value, average daily share
volume and seasoning as a public company. The Index is ranked on a semi-annual
basis in May and November. For more information about the NASDAQ Biotechnology
Index, including eligibility criteria, visit http://www.nasdaq.com/.
The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology
Index(SM) Fund (AMEX:IBB), which seeks investment results that generally
correspond to the price and yield performance of the NASDAQ Biotechnology Index
before fees and expenses. In addition, options based on the NASDAQ
Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on
various exchanges.
NASDAQ is the world's largest electronic stock market. With approximately 3,400
companies, it lists more companies and, on average, trades more shares per day
than any other U.S. market. It is home to category-defining companies that are
leaders across all areas of business including technology, retail,
communications, financial services, media and biotechnology.
For more information about NASDAQ, visit the NASDAQ Web site at
http://www.nasdaq.com/ or the NASDAQ Newsroom(SM) at http://www.nasdaqnews.com/
The FTSE Global Classification System is compiled by FTSE International Limited.
(C)FTSE International Limited 2003.
FTSE(TM) is a trademark of the London Stock Exchange Plc and The Financial Times
Limited and is used by FTSE International Limited under license.
iShares are distributed by SEI Investments Distribution Co. Barclays Global
Fund Advisors serves as an advisor to iShares and is a subsidiary of Barclays
Global Investors, N.A., neither of which is affiliated with SEI. For a
prospectus, call 1-800-iSHARES (1-800-474-2737).
IShares are not FDIC Insured.
Have No Bank Guarantee.
May Lose Value.
Company Briefs Source: Bloomberg
aaiPharma Inc. (NASDAQ:AAII) is a specialty pharmaceutical and product
development company with drug development capabilities in the United States,
Europe, and Asia. The Company partners with pharmaceutical companies on both a
fee-for-service and royalty payment basis. aaiPharma is also focusing on the
launching of its own brand of products in the areas of immunosuppression and
pain management.
Able Laboratories, Inc. (NASDAQ:ABRX) develops and manufactures generic
pharmaceuticals. The Company focuses on developing products that offer market
opportunities within selected niche markets of the generic drug industry. Able
currently sells several products and has several products in various stages of
Federal Drug Administration approval.
Adolor Corporation (NASDAQ:ADLR) is a therapeutic-based biopharmaceutical
company. The Company discovers, develops, and commercializes pharmaceutical
products for the treatment of pain and the side effects that are caused by
current narcotic pain treatments. Adolor's small molecule product candidates
are in clinical trials.
AtheroGenics, Inc. (NASDAQ:AGIX) develops and commercializes small molecule
therapeutics for the treatment of chronic inflammatory diseases such as
atherosclerosis, asthma, and arthritis. These treatments are designed to
suppress inflammation without undermining the body's ability to protect itself
against infection.
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI) develops drug-coated medical
devices and drug-loaded surgical implants. The Company enhances the performance
of medical devices and surgical implants through the use of
pharmacotherapeutics. Angiotech is the original developer of the paclitaxel-
eluting coronary stent, a drug-loaded medical device.
American Pharmaceutical Partners, Inc. (NASDAQ:APPX) develops, manufactures, and
markets injectable pharmaceutical products. The Company's primary focus is on
the oncology, anti-infective, and critical care markets.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) discovers and develops breakthrough
medicines that regulate cell signaling with small molecules. The Company is
primarily focused on product candidates for targeted indications. ARIAD is
developing products to treat solid tumors, to block the spread of cancer, to
treat certain forms of leukemia, and to treat cancer that has spread to bone and
primary bone cancers.
Axcan Pharma Inc. (NASDAQ:AXCA) is a pharmaceutical company. The Company
researches, develops, and distributes pharmaceutical products, mainly in the
field of gastroenterology. Axcan's products treat inflammatory bowel diseases,
irritable bowel syndrome, cholestatic diseases of the liver, and infections as
encountered in cystic fibrosis patients.
Biopure Corporation (NASDAQ:BPUR) develops, manufactures, and markets Oxygen
Therapeutic solutions. The Company's products are pharmaceuticals which are
intravenously administered to deliver oxygen to the body's tissues. Biopure's
products include Oxyglobin, a treatment for anemia in dogs, and Hemopure, an
investigational Oxygen Therapeutic solution for human use.
Biosite Incorporated (NASDAQ:BSTE) is a research-based company that discovers
and develops novel protein-based diagnostic tests. The Company's products
improve a physician's ability to diagnose debilitating and life- threatening
diseases. Biosite's Triage brand rapid diagnostic tests are used in United
States hospitals and international markets.
Ciphergen Biosystems, Inc. (NASDAQ:CIPH) develops, manufactures, and markets a
proprietary ProteinChip System that enables protein discovery, characterization,
and assay development. The system provides better understanding of biological
functions at the protein level.
Connetics Corporation (NASDAQ:CNCT) is a pharmaceutical company focused on
late-stage product development and commercialization for dermatology and other
specialty medical markets. The Company currently markets Luxiq foam for the
treatment of scalp dermatoses, Ridaura for the treatment of rheumatoid
arthritis, and Actimmune for the treatment of infections resulting from chronic
granulomatous disease.
deCODE genetics, Inc. (NASDAQ:DCGN) is developing gene and drug target
discovery, database, and information technology products and services for the
healthcare industry using human genetics. The Company develops and applies
information technology to discover new knowledge about health and disease
through data mining.
Digene Corporation (NASDAQ:DIGE) develops, manufactures, and markets DNA and RNA
tests for the detection, screening, and monitoring of human diseases. The
Company's products are designed to help improve clinical outcomes and reduce the
overall cost of disease management. Digene's lead product aids physicians in
identifying women who are at a high risk for cervical cancer and disease.
Dendreon Corporation (NASDAQ:DNDN) discovers and develops immunologically based
therapeutic products for the treatment of cancer. The Company combines
knowledge in immunology and antigen engineering with proprietary cell separation
technologies to develop therapeutic vaccines that induce cell- mediated
immunity, the body's key defense against cancer.
Eon Labs, Inc. (NASDAQ:ELAB) develops, licenses, manufactures, sells, and
distributes a range of prescription pharmaceutical products. The Company
utilizes an integrated approach to select and develop generic pharmaceutical
products in both niche and high volume markets. Eon focuses on drugs in a broad
range of solid oral dosage forms, utilizing both immediate and sustained release
delivery.
Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) discovers, develops, and
commercializes novel drugs, focusing on small molecule drug development and
vascular biology. The Company's initial product, Argatroban, is being marketed
for heparin-induced thrombocytopenia. Encysive is also developing the
endothelin antagonist, sistaxsentan, for pulmonary arterial hypertension.
Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) is a specialty pharmaceutical
company with products that provide pain management. The Company researches,
develops, produces, and markets both branded and generic pharmaceuticals.
Endo's products include Percocet, Percodan, and Lidoderm.
EPIX Medical, Inc. (NASDAQ:EPIX) develops targeted contrast agents to improve
the capability of magnetic resonance imaging (MRI) as a diagnostic tool for a
variety of diseases. The Company's principal product under development,
AngioMARK, is an investigational new drug designed to enhance MRI.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) discovers and develops pharmaceutical
products for the treatment of cardiovascular disease. The Company is testing
therapies that may enhance the naturally occurring processes in the body for the
removal of excess cholesterol.
EXACT Sciences Corporation (NASDAQ:EXAS) has developed technologies that will
enable genomics based detection of colorectal cancer and other types of common
cancer. The Company's technologies isolate human DNA shed into stool and then
detect the minute amount of abnormal DNA associated with colorectal cancer.
First Horizon Pharmaceutical Corporation (NASDAQ:FHRX) is a pharmaceutical
company focused on the development and marketing of prescription pharmaceuticals
for the treatment of chronic diseases. The Company currently markets
prescription products to high prescribing physicians throughout the United
States.
Flamel Technologies S.A. (NASDAQ:FLML) develops polymer technologies for
applications such as drug delivery, biomaterials, and agrochemicals. The
Company's programs include "Micropump" and "Medusa" in drug delivery, and
"ColCys" in biomaterial-based medical devices. Flamel builds on its technology
platforms to develop other products, such as new materials for opthalmic lens
products.
Gen-Probe Incorporated (NASDAQ:GPRO) develops, manufactures, and commercializes
diagnostic products based on its genetic probe technologies.
Harvard Bioscience, Inc. (NASDAQ:HBIO) develops, manufactures, and markets tools
used in drug discovery research and pharmaceutical and biotechnology companies,
universities, and government laboratories. The Company's tools include
proteomics products that allow researchers to purify and analyze proteins and
ADMET screening products that test drug candidates.
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) discovers, develops, and
commercializes products for the treatment of a number of targeted disease states
caused by viral, bacterial, parasitic, or fungal infections. The Company's
technology platforms are based on cellular energy regulation, an immune system
modulation technology, and on biochemical synthesis regulators.
Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) develops and commercializes products
and product candidates, including multiple compounds in late-stage clinical
development. The Company is developing compounds for the treatment of panic
disorders, overactive bladder, cirrhosis of the liver, strokes, and inflammatory
bowel disease, as well as a compound for the prevention of infection by certain
diseases.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) provides diagnostic, detection, and
information systems for veterinary, food, and water testing applications. The
Company also operates an international network of veterinary reference
laboratories. IDEXX offers its products to customers worldwide.
Introgen Therapeutics, Inc. (NASDAQ:INGN) develops gene therapy products for the
treatment of cancer. The Company's lead product candidate combines the p53
gene, a tumor suppressor gene, with a gene delivery system that it has developed
and tested. Introgen is developing cancer therapies that are based on restoring
normal cellular function through gene therapy.
Impax Laboratories, Inc. (NASDAQ:IPXL) develops, manufactures, and markets both
proprietary and multi-source pharmaceutical products utilizing its drug delivery
technologies. The Company specializes in the development of niche and
controlled release generics, as well as the development of branded products.
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) discovers and develops
pharmaceutical products to treat diseases that result from deficiencies in the
body's natural mechanisms of mucosal hydration. The Company's lead products
target respiratory and opthtalmic diseases with inadequate current treatments,
including a respiratory for chronic bronchitis and an opthtalmic for dry eye
disease.
Kos Pharmaceuticals, Inc. (NASDAQ:KOSP) is a fully integrated specialty
pharmaceutical company that develops and commercializes proprietary prescription
pharmaceutical products. The Company's products are for use in the treatment of
chronic cardiovascular and respiratory diseases. Kos has drug-delivery
capabilities in both solid-dose and aerosolized formulation technologies.
Lexicon Genetics Incorporated (NASDAQ:LEXG) discovers breakthrough treatments
for human disease. The Company is using gene knockout technology to
systematically discover the physiological functions and pharmaceutical utility
of genes. Lexicon's gene function discoveries fuel therapeutic discovery
programs in diabetes, obesity, cardiovascular disease, immune disorders, and
cancer.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) researches and develops
specialized therapeutics for the treatment of diseases caused by antibodies. The
Company is developing products to treat autoimmune conditions such as lupus and
antibody-mediated stroke.
Martek Biosciences Corporation (NASDAQ:MATK) develops, manufactures, and sells
products derived from microalgae. The Company's products include nutritional
oils for infant formula, nutritional supplements and food ingredients, reagents
to visualize molecular interactions for drug discovery and development, and
fluorescent markers for diagnostics, miniaturized screening, and gene
detection.
Vicuron Pharmaceuticals Inc. (NASDAQ:MICU) is an international biopharmaceutical
company that discovers, develops, manufactures, and commercializes vital
medicine for seriously ill patients. The Company's lead product candidates
include a novel antifungal agent and a novel intravenous antibiotic for the
treatment of serious Gram-positive infections.
Nabi Biopharmaceuticals (NASDAQ:NABI) is a vertically integrated
biopharmaceutical company focused on drugs that prevent and treat infectious and
autoimmune diseases. The Company currently provides biopharmaceuticals,
including Nabi-HB for the prevention of hepatitis B infections, and WinRho SDF
for the treatment of HIV-related immune thrombocytopenia. Nabi also has a
clinical trials program.
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) develops transdermal and transmucosal
drug delivery systems and technologies. The Company's products include Vivelle
and Vivelle Dot estrogen transdermal delivery systems, DentiPatch transmucosal
patch, and CombiPatch and Estalis estrogen/progestin transdermal delivery
systems. Noven also has other products in development.
Neurochem Inc. (NASDAQ:NRMX) is a specialty pharmaceutical company that offers a
new class of drug candidates to prevent and stop the progression of diseases for
which no cure exists. The Company is focusing on unmet medical needs of
disorders of the central nervous system and amyloid-related diseases.
Neurochem's product candidates include Fibrillex, Alzhemed, and Cerebril.
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) discovers and develops novel
therapeutics based upon the genetics of human disease, with an emphasis on
cancer. The Company focuses on defining the function of certain mutated genes
that are known to cause cancer, and on developing therapies to reverse the
effects of the mutation or to kill the cancer cell.
Priority Healthcare Corporation (NASDAQ:PHCC) distributes specialty
pharmaceuticals and related medical supplies to the alternate healthcare market.
The Company also provides patient-specific, self-injectable biopharmaceuticals
and disease treatment programs to individuals with chronic diseases. Priority
distributes its products across the United States.
POZEN Inc. (NASDAQ:POZN) develops pharmaceutical products in select therapeutic
areas. The Company's MT 100 product is an oral first-line therapy for the
treatment of migraine. POZEN also develops drugs for diseases of the
gastrointestinal and respiratory tracts, oncology, and infectious diseases.
Penwest Pharmaceuticals Co. (NASDAQ:PPCO) researches, develops, and
commercializes novel drug delivery technologies. The Company's proprietary
TIMERx controlled release drug delivery technology is applicable to a broad
range of orally administered drugs. Penwest's product portfolio ranges from
excipients that are sold in bulk, to more advanced and patented excipients that
are licensed to customers.
Perrigo Company (NASDAQ:PRGO) manufactures store brand over-the-counter
pharmaceutical products and also manufactures store brand nutritional products.
The Company's customers include major national and regional retail drug,
supermarket, and mass merchandise chains such as Albertson's, CVS, and Target,
and major wholesalers such as Super Valu and McKesson.
PAREXEL International Corporation (NASDAQ:PRXL) is a contract research and
product launch organization. The Company provides outsourcing services to the
worldwide pharmaceutical, biotechnology and medical device industries. PAREXEL
has operations in various countries around the world.
Pain Therapeutics, Inc. (NASDAQ:PTIE) is developing a new generation of opioid
painkillers. The Company uses its proprietary technology to reformulate opioid
drugs, such as morphine, into new painkillers. Pain Therapeutics currently has
several products in Phase II clinical trials.
Sepracor Inc. (NASDAQ:SEPR) is a research-based pharmaceutical company dedicated
to treating and preventing human disease through the discovery, development, and
commercialization of innovative pharmaceutical products that are directed to
unmet medical needs. The company's drug development programs are focused on the
treatment of respiratory, urology, and central nervous system disorders.
SFBC International, Inc. (NASDAQ:SFCC) is a contract research organization that
conducts clinical research and provides drug development services for clients in
the pharmaceutical and biotechnology industries.
Shire Pharmaceuticals Group plc (NASDAQ:SHPGY) specializes in the marketing,
licensing and development of prescription medicines. The Group focuses its
operations towards four therapeutic areas: central nervous system disorders,
oncology/hematology, antivirals and biologics. Shire sells and markets its
products in the United States, Canada, Ireland, France, Germany, Italy, Spain,
and the United Kingdom.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) develops and markets prescription
pharmaceutical products for the treatment of gastrointestinal diseases. The
Company's COLAZAL product is an anti-inflammatory drug used for the treatment of
mildly to moderately active ulcerative colitis.
SuperGen, Inc. (NASDAQ:SUPG) is a pharmaceutical company that acquires,
develops, and markets products for the treatment of life-threatening diseases,
particularly cancer. The Company is marketing Nipent in the United States for
the treatment of hairy cell leukemia. SuperGen is also conducting late stage
clinical trials on a drug that has the potential to treat a variety of solid
tumors.
Savient Pharmaceuticals Inc. (NASDAQ:SVNT) develops, manufactures, and markets
human health care products for niche and wider markets. The Company markets
Oxandrin and Delatestryl in the United States. Savient's United Kingdom
subsidiary develops oral liquid formulations of prescription products, and its
Israeli subsidiary manufactures Bio-Tropin, BioLon, Bio-Hep-B, and Arthrease.
Taro Pharmaceutical Industries Ltd. (NASDAQ:TARO) is a multinational,
science-based pharmaceutical company that discovers, develops, manufactures, and
markets healthcare products. The Company's products include prescription and
over-the-counter drugs.
Techne Corporation (NASDAQ:TECH), through Research and Diagnostic Systems, Inc.,
manufactures biological products. The Company also, through R&D Systems Europe,
Ltd., distributes biotechnology products.
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) develops, manufactures and
markets generic and branded human pharmaceuticals and active pharmaceutical
ingredients. The Company produces antibiotics, oncological products, Alpha D3
for treatment of post-menopausal bone loss in women and Copaxone for treatment
of multiple sclerosis. Teva develops novel drugs for diseases of the central
nervous system.
DATASOURCE: NASDAQ
CONTACT: Media: Wayne Lee, +1-301-978-4875, or Issuers and Investors:
Lisa Chaney, +1-301-978-8281, both of NASDAQ
Web site: http://www.nasdaqnews.com/
http://www.nasdaq.com/